Paper · 35688802

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

Coombes RC and 20 others. Nat Commun, 2022. Cited by 64 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Papers, record 35688802. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35688802

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.; PubMed
Journal: Nat Commun; PubMed
Year: 2022; PubMed
Publication types: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/35688802/; PubMed
DOI: https://doi.org/10.1038/s41467-022-30666-0; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9187670/; PubMed
The journal: https://conductscience.org/library/journal-index/101528555; PubMed
Citations, by iCite: 64; iCite
Relative citation ratio, by iCite: 4.39; iCite
Revised in PubMed: 2025-05-30; PubMed

Authors21

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Coombes RC	R C	https://orcid.org/0000-0002-4811-1100
2	Badman PD	P D	https://orcid.org/0000-0002-0337-3190
3	Lozano-Kuehne JP	J P	https://orcid.org/0000-0002-7372-0725
4	Liu X	X
5	Macpherson IR	I R	https://orcid.org/0000-0003-4295-8885
6	Zubairi I	I
7	Baird RD	R D	https://orcid.org/0000-0001-7071-6483
8	Rosenfeld N	N	https://orcid.org/0000-0002-2825-4788
9	Garcia-Corbacho J	J	https://orcid.org/0000-0002-6109-8449
10	Cresti N	N	https://orcid.org/0000-0002-0495-4472

1 to 10 of 21Source PubMed

See all 21 authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Benzamides	Major topic
Breast Neoplasms	Major topic
Piperazines	Major topic
Pyrazoles	Major topic
Antineoplastic Agents
Female
Humans
Treatment Outcome

Source PubMed

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	Stated by
27307C0011	NIEHS NIH HHS	United States	PubMed
11906	Cancer Research UK	United Kingdom	PubMed
27305C0011	NIEHS NIH HHS	United States	PubMed
	Department of Health	United Kingdom	PubMed
27398C0011	NIEHS NIH HHS	United States	PubMed
28292	Cancer Research UK	United Kingdom	PubMed
C1312/A12956	Cancer Research UK	United Kingdom	PubMed
20240	Cancer Research UK	United Kingdom	PubMed

Source PubMed

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record
NCT01791985	AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)	Derived from the trial	Yes

Source ClinicalTrials.gov

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers
Erratum in	36,650,166	Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.	https://conductscience.org/library/papers/36650166

Source PubMed

References18

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	32,723,837	Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer.	Clin Cancer Res	2020	https://conductscience.org/library/papers/32723837	PubMed
2	28,615,371	A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.	Clin Cancer Res	2017	https://conductscience.org/library/papers/28615371	PubMed
3	31,405,822	Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.	Lancet Oncol	2019	https://conductscience.org/library/papers/31405822	PubMed
4	26,181,262	Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.	JAMA Oncol	2015	https://conductscience.org/library/papers/26181262	PubMed
5	19,097,774	New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).	Eur J Cancer	2009	https://conductscience.org/library/papers/19097774	PubMed
6	28,070,720	Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.	Invest New Drugs	2017	https://conductscience.org/library/papers/28070720	PubMed
7	25,220,842	Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.	Int J Cancer	2015	https://conductscience.org/library/papers/25220842	PubMed
8	29,177,434	A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.	Ann Oncol	2017	https://conductscience.org/library/papers/29177434	PubMed
9	7,657,392	Expression of 2 variant forms of fibroblast growth factor receptor 1 in human breast.	Int J Cancer	1995	https://conductscience.org/library/papers/7657392	PubMed
10	28,183,331	Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.	Breast Cancer Res	2017	https://conductscience.org/library/papers/28183331	PubMed

1 to 10 of 18

See all 18 references

Cited by49

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 64 citations.

PMID	Title	Journal	Year	In Papers	Source
42,633,326	Advances in FGF/FGFR Signaling: Implications for Disease and Therapy.	MedComm (2020)	2026	https://conductscience.org/library/papers/42633326	PubMed
42,617,046	FGFR1 Suppresses STING-Mediated Interferon Response in Endocrine Therapy-Resistant Breast Cancer.	Cancer Res Commun	2026	https://conductscience.org/library/papers/42617046	PubMed
42,446,762	Rewiring cancer cell fate toward vasculogenic mimicry: from classical to unconventional processes.	Cancer Metastasis Rev	2026	https://conductscience.org/library/papers/42446762	PubMed
42,394,340	FGFR Inhibitor AZD4547 Disrupts Inflammatory CAF Crosstalk With Cancer Cells and Macrophages and Attenuates Metastasis in Pancreatic Cancer.	FASEB J	2026	https://conductscience.org/library/papers/42394340	PubMed
42,218,196	Conserved mRNA expression patterns of the Klotho family in canine mammary tumors and human breast cancer.	Sci Rep	2026	https://conductscience.org/library/papers/42218196	PubMed
42,209,519	Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of estrogen receptor-positive breast cancer brain metastases.	Nat Commun	2026	https://conductscience.org/library/papers/42209519	PubMed
42,196,611	CAFs and Endocrine Therapy Resistance in Hormone Receptor-Positive Breast Cancer.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42196611	PubMed
42,156,709	Stattic enhances the anti-tumor activity of AZD4547 in LUSC by blocking STAT3/RRM2-mediated DNA repair and inducing ROS-driven mitochondrial dysfunction.	Cell Death Dis	2026	https://conductscience.org/library/papers/42156709	PubMed
41,615,925	Uralenol, Glycyrol, and Abyssinone II as potent inhibitors of fibroblast growth factor receptor 2 from anti-cancer plants: A deep learning and molecular dynamics approach.	PLoS One	2026	https://conductscience.org/library/papers/41615925	PubMed
41,351,070	Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.	BMC Cancer	2025	https://conductscience.org/library/papers/41351070	PubMed

1 to 10 of 49

See all 49 cited by

Genes23

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
ATHS	470	PubTator's text mining	https://conductscience.org/library/genes/470	NCBI Gene
CHGA	1,113	PubTator's text mining	https://conductscience.org/library/genes/1113	NCBI Gene
CYP19A1	1,588	PubTator's text mining	https://conductscience.org/library/genes/1588	NCBI Gene
CYP2D6	1,565	PubTator's text mining	https://conductscience.org/library/genes/1565	NCBI Gene
CYP3A4	1,576	PubTator's text mining	https://conductscience.org/library/genes/1576	NCBI Gene
ERBB2	2,064	PubTator's text mining	https://conductscience.org/library/genes/2064	NCBI Gene
EREG	2,069	PubTator's text mining	https://conductscience.org/library/genes/2069	NCBI Gene
ESR1	2,099	PubTator's text mining	https://conductscience.org/library/genes/2099	NCBI Gene
FGF10	2,255	PubTator's text mining	https://conductscience.org/library/genes/2255	NCBI Gene
FGF2	2,247	PubTator's text mining	https://conductscience.org/library/genes/2247	NCBI Gene

1 to 10 of 23

See all 23 genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets	Source
ANASTROZOLE	CHEMBL1399	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL1399	ChEMBL
LETROZOLE	CHEMBL1444	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL1444	ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35688802

GET https://conductscience.org/api/papers/v1/35688802/authors?page=2

API reference For AI assistants